Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580420 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
A Phase 2 study of End Stage Renal Disease and Primary Hyperoxaluria Type 1, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 18
- Study locations
NCT04580420: Recruiting Phase 2 study of End Stage Renal Disease and Primary Hyperoxaluria Type 1, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
NCT04580420 is a Phase 2 study of End Stage Renal Disease and Primary Hyperoxaluria Type 1 that is actively recruiting participants, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 28 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The trial reports 18 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04580420, a Phase 2 study of End Stage Renal Disease and Primary Hyperoxaluria Type 1, is actively recruiting participants, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 18
- Study locations
Study Summary
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
Primary Outcome
To assess the efficacy of DCR-PHXC in lowering Pox in participants with PH1 and severe renal impairment, with or without hemodialysis or peritoneal dialysis.
Conditions Studied
Interventions
- DRUG DCR-PHXC
Study Locations (18)
Other
- Clinical Trial Site - Bron
- Clinical Trial Site - Paris
- Clinical Trial Site - Bonn
- Clinical Trial Site - Heidelberg
- Clinical Trial Site - Roma
- Clinical Trial Site - Beirut
- Clinical Trial Site - Casablanca
- Clinical Trial Site - Oradea
- Clinical Trial Site - Oradea
- Clinical Trial Site - Barcelona
- Clinical Trial Site - Santa Cruz de Tenerife
- Clinical Trial Site - Dubai
- Clinical Trial Site - London
- Clinical Trial Site - London
California
- Clinical Trial Site - San Francisco
Massachusetts
- Clinical Trial Site - Boston
Minnesota
- Clinical Trial Site - Rochester
New York
- Clinical Trial Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2032-01-30 |
| Phase | Phase 2 |
What NCT04580420 shows while recruiting
NCT04580420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which DCR-PHXC is the first listed.
NCT04580420 lists 18 locations in 5 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04580420 about?
NCT04580420 is a clinical study titled "Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD". The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
What is the current status of trial NCT04580420?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-04-15. Estimated completion is 2032-01-30.
What conditions does trial NCT04580420 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Primary Hyperoxaluria Type 1.
What interventions are being tested in trial NCT04580420?
The interventions under investigation include: DCR-PHXC (DRUG).
Who is sponsoring clinical trial NCT04580420?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04580420 being conducted?
This trial has 18 study locations across California, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04580420's enrollment target sits among peer trials
28 63rd of 86 higher than 23 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Communication During Hospitalization About Resuscitation Trial
ACTIVE NOT RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
-
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI